Physician profile
Scott A Schneider
NPI 1639141179
$24,409.84
in general payments reported to CMS, 2019-2025
23 companies · $310 in 2025
The $310 reported for 2025 was more than what a typical Child & Adolescent Psychiatry provider received nationally (typical 2025 total: $132).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $270 · 2020: $41.59 · 2021: $21K · 2022: $2,035 · 2023: $36.28 · 2024: $758 · 2025: $310.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,104.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,103.91 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Supernus Pharmaceuticals, INC. | $23,240.82 | 2021-2024 | Qelbree |
| Corium, LLC | $172.85 | 2023-2025 | Azstarys |
| Otsuka America Pharmaceutical, INC. | $145.83 | 2019-2025 | Rexulti, Abilify Maintena |
| Teva Pharmaceuticals USA, INC. | $103.50 | 2024-2025 | Uzedy, Austedo Xr |
| Bioxcel Therapeutics, INC. | $82.90 | 2024 | Igalmi |
| Janssen Pharmaceuticals, INC | $81.39 | 2024-2025 | Invega Sustenna, Spravato, Invega Trinza |
| Vanda Pharmaceuticals INC. | $79.79 | 2024-2025 | Fanapt |
| Neos Therapeutics, LP | $71.55 | 2019 | |
| Harmony Biosciences LLC | $58.77 | 2025 | |
| Shire North American Group INC | $57.79 | 2019 | |
| Noven Therapeutics, LLC | $46.97 | 2024 | Secuado, Xelstrym |
| Takeda Pharmaceuticals U.S.A., INC. | $42.97 | 2019-2020 | |
| Alkermes, INC. | $40.25 | 2025 | Aristada, Lybalvi |
| Sunovion Pharmaceuticals INC. | $37.86 | 2019-2020 | |
| Almatica Pharma LLC | $22.40 | 2024 | Loreev Xr |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tris Pharma INC | $19.52 | 2024 | Dyanavel Xr |
| Ironshore Pharmaceuticals INC. | $19.02 | 2024 | |
| Lundbeck LLC | $17.47 | 2019 | |
| Axsome Therapeutics, INC. | $16.38 | 2025 | Auvelity |
| Avanir Pharmaceuticals, INC. | $14.91 | 2019 | |
| Neurocrine Biosciences, INC. | $13.67 | 2024 | Ingrezza |
| Merck Sharp & Dohme LLC | $12.25 | 2019 | |
| Jazz Pharmaceuticals INC. | $10.98 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Scott Schneider listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.